Núcleo de Pós-Graduação e Pesquisa da Santa Casa de Belo Horizonte, MG, Brazil Rua Domingos Vieira, 590 - 30150240, Belo Horizonte, Brazil.
Núcleo de Pós-Graduação e Pesquisa da Santa Casa de Belo Horizonte, MG, Brazil Rua Domingos Vieira, 590 - 30150240, Belo Horizonte, Brazil; Departamento de Alimentos, Escola de Nutrição, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil.
Microb Pathog. 2018 Aug;121:359-362. doi: 10.1016/j.micpath.2018.05.039. Epub 2018 May 24.
Paracoccidioidomycosis (PCM) is a chronic mycosis caused by the saprobic and dimorphic species Paracoccidioides brasiliensis and P. lutzii. This disease is prevalent in Latin American countries. PCM appears as a relevant concern and challenge for the mycologists, since until now there is no a methodology suitable for an efficient and safe diagnosis and species identification. Thus, the present study aimed to validate a methodology for PCM´s diagnosis, using quantitative Polymerase Chain Reaction (qPCR) through target amplification of the gene encoding the recombinant protein Pb27, a common protein to the both species Paracoccidioides brasiliensis and P. lutzii. The experiments were performed in vitro to determine the specificity, efficiency and detection limit of qPCR assay, using specific primers and probe, which sequences were subject to a patent deposited in Brazilian CTIT, under the registration number: BR1020160078830. According to the results the technique showed sensitivity of 94% and specificity of 100%, demonstrating that it will be possible to develop a new fast and safe diagnostic PCM and can be standardized in order to present a low cost, accessible to the patient served by the public health system in Brazil and Latin America.
球孢子菌病(PCM)是一种由腐生和二态物种巴西副球孢子菌和 P. lutzii 引起的慢性真菌病。这种疾病在拉丁美洲国家流行。PCM 对真菌学家来说是一个重要的关注和挑战,因为到目前为止,还没有一种适合高效和安全诊断及物种鉴定的方法。因此,本研究旨在通过靶向扩增编码重组蛋白 Pb27 的基因来验证一种用于 PCM 诊断的方法,该基因是巴西副球孢子菌和 P. lutzii 共有的一种蛋白。实验在体外进行,以确定 qPCR 检测的特异性、效率和检测限,使用特定的引物和探针,其序列已在巴西 CTIT 申请专利,注册号为:BR1020160078830。根据结果,该技术显示出 94%的敏感性和 100%的特异性,表明有可能开发出一种新的快速、安全的 PCM 诊断方法,并可标准化,以提供低成本,使巴西和拉丁美洲公共卫生系统服务的患者都能负担得起。